Myelodysplastic Syndromes

Bristol Myers Squibb

Pharma

BMS scores a topline treat in Reblozyl phase 3 study

Another key drug from Bristol Myers Squibb’s Celgene buyout might be on its way to an additional indication after an interim analysis.

Zoey Becker Oct 31, 2022 12:00pm

Teva

Teva launches Revlimid generic, the first to do so in U.S.

Mar 7, 2022 11:11am